Tower Research Capital LLC TRC Sells 6,114 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Tower Research Capital LLC TRC lessened its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 56.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,640 shares of the company’s stock after selling 6,114 shares during the period. Tower Research Capital LLC TRC’s holdings in Nkarta were worth $31,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Monaco Asset Management SAM bought a new stake in shares of Nkarta during the 3rd quarter valued at approximately $327,000. Innovis Asset Management LLC bought a new stake in shares of Nkarta during the third quarter worth $193,000. Acadian Asset Management LLC acquired a new position in shares of Nkarta during the third quarter worth $89,000. Forefront Analytics LLC lifted its stake in shares of Nkarta by 282.5% in the 3rd quarter. Forefront Analytics LLC now owns 39,657 shares of the company’s stock valued at $55,000 after acquiring an additional 29,290 shares during the last quarter. Finally, abrdn plc acquired a new stake in shares of Nkarta during the 4th quarter valued at $191,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Insiders Place Their Bets

In related news, Director Simeon George acquired 2,000,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the acquisition, the director now owns 1,548,341 shares of the company’s stock, valued at $15,483,410. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Simeon George acquired 2,000,000 shares of Nkarta stock in a transaction on Wednesday, March 27th. The stock was purchased at an average price of $10.00 per share, with a total value of $20,000,000.00. Following the completion of the purchase, the director now owns 1,548,341 shares of the company’s stock, valued at approximately $15,483,410. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider James Trager sold 4,143 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $12.00, for a total value of $49,716.00. Following the sale, the insider now owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Mizuho lowered their target price on Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday, March 22nd. HC Wainwright dropped their price objective on shares of Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of Nkarta in a report on Wednesday, April 10th. Raymond James reaffirmed an “outperform” rating and set a $16.00 price target (up previously from $13.00) on shares of Nkarta in a research note on Friday, March 22nd. Finally, Canaccord Genuity Group boosted their price objective on shares of Nkarta from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Nkarta currently has a consensus rating of “Buy” and a consensus target price of $17.83.

Nkarta Stock Performance

Shares of NASDAQ:NKTX traded down $0.13 during trading on Friday, reaching $7.40. The stock had a trading volume of 820,344 shares, compared to its average volume of 936,655. Nkarta, Inc. has a 52 week low of $1.28 and a 52 week high of $16.24. The firm’s fifty day moving average is $10.15 and its 200 day moving average is $7.15. The stock has a market cap of $365.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.88.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.05. On average, research analysts forecast that Nkarta, Inc. will post -2.36 earnings per share for the current fiscal year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.